Meriofert Spuit

Follicle‑Stimulating Hormone, Luteinising Hormone, the active ingredient in Meriofert Spuit, is a gonadotropin presented as a sterile injectable solution for subcutaneous use. It is employed to stimulate ovarian follicular development and ovulation in women with anovulatory infertility, and to replace deficient gonadotropins in hypogonadotropic hypogonadism. GNH USA supplies Meriofert Spuit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Spuit contains gonadotropins that act on the hypothalamic‑pituitary‑ovarian axis to support reproductive function. - Infertility due to anovulation: promotes follicular growth and ovulation to enable conception. - Controlled ovarian stimulation: enhances multiple follicle development for assisted reproductive technologies such as IVF. - Hypogonadotropic hypogonadism: replaces deficient endogenous FSH and LH to restore normal ovarian activity.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Headache: transient, often resolves without intervention. - Nausea: mild gastrointestinal upset. - Abdominal bloating: sensation of fullness or distension. - Mild ovarian hyperstimulation: limited ovarian enlargement without systemic signs.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): severe ovarian enlargement, fluid shift, and thromboembolic risk. - Multiple pregnancy: increased chance of twins or higher order gestations. - Allergic reaction: rash, urticaria, or anaphylaxis. - Severe abdominal pain: may indicate complications such as ovarian torsion. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Ectopic pregnancy: implantation outside the uterine cavity.

Use of Meriofert Spuit requires careful clinical monitoring to minimise risks. - Baseline assessment: evaluate ovarian reserve and hormonal profile before initiation. - Monitoring: measure serum estradiol and ultrasound follicle size during treatment. - Pregnancy avoidance: do not administer to women who are already pregnant. - Specialist supervision: treatment should be overseen by a reproductive endocrinologist. - Dose adjustment: consider renal or hepatic impairment when determining dose. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may affect efficacy or safety of Meriofert Spuit.

Major Interactions (Avoid): - Human chorionic gonadotropin (hCG) co‑administration: markedly increases risk of OHSS. - High‑dose estrogen therapy: may blunt gonadotropin response. - GnRH agonist trigger without proper timing: can precipitate severe OHSS.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may require washout period before starting therapy. - Anticoagulants: monitor for thrombotic complications if OHSS develops. - Corticosteroids: may alter hormone metabolism. - Thyroid hormone replacement: adjust dosing if thyroid status changes. - Anti‑emetic agents: may mask early symptoms of OHSS.